Coronavirus disease

Over $ 500 Million Growth in Global Anti-Fatigue Mat Market 2021-2025 | Includes Insights on Key Products Offered by Major Vendors | Technavio

Retrieved on: 
Wednesday, March 10, 2021
Articles, Health, Occupational safety and health, Public health, Infectious diseases, COVID-19 pandemic, Coronavirus disease, Fatigue, COVID-19 lockdowns, Mat

NEW YORK, March 10, 2021 /PRNewswire/ -- The anti-fatigue mat market is expected to grow by USD 501.25 million during 2021-2025, according to Technavio.

Key Points: 
  • NEW YORK, March 10, 2021 /PRNewswire/ -- The anti-fatigue mat market is expected to grow by USD 501.25 million during 2021-2025, according to Technavio.
  • Download Our Free Sample Report to Know More
    The anti-fatigue mat market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • As per Technavio's pandemic-focused market research, market growth increased in 2020 as compared to 2019.
  • Get report snapshot here to get a detailed market share analysis of market participants during COVID-19 lockdown: https://www.technavio.com/report/anti-fatigue-mat-market-industry-analysis
    Anti-fatigue mat market is segmented as below:

Global X-Ray Security Screening Market with COVID-19 Vaccines Impact Analysis 2021-2027

Retrieved on: 
Tuesday, March 9, 2021
Health, Occupational safety and health, Articles, Medical research, COVID-19 pandemic, Pandemics, Coronavirus disease, COVID-19 vaccine

DUBLIN, March 9, 2021 /PRNewswire/ -- The "X-Ray Security Screening (Aviation, Maritime, Land Transportation, Defense, Postal, Perimeter, Building, Baggage, Cargo, People, Container & Vehicle) Market with COVID-19 Vaccines Impact Analysis - 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 9, 2021 /PRNewswire/ -- The "X-Ray Security Screening (Aviation, Maritime, Land Transportation, Defense, Postal, Perimeter, Building, Baggage, Cargo, People, Container & Vehicle) Market with COVID-19 Vaccines Impact Analysis - 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • This report contains a thorough analysis of 6 vertical and 6 technology sectors, 5 regional and 24 national markets, detailing 2020-2027 market size of 156 sub-markets.
  • According to the report, the 2021-2027 X-Ray Security Screening Systems market is affected by the following drivers and inhibitors:
    The COVID-19 pandemic changed the world.
  • New COVID-19 vaccines having an extremely high efficacy mean that the X-Ray Security Screening market will recover by 2022.

SARS-CoV-2 (COVID-19) Vaccine Industry to Reach $47.5 Billion by 2026 - Initial Revenue Drop Will Occur in 2022, due to Vaccine Pricing Reductions Resulting from Increased Competition

Retrieved on: 
Tuesday, March 9, 2021
COVID-19 vaccines, COVID-19, Clinical trials, Health sciences, Medicine, Medical research, Adenoviridae, Vaccination, COVID-19 vaccine, Coronavirus disease, Vaccine, Johnson & Johnson COVID-19 vaccine

DUBLIN, March 9, 2021 /PRNewswire/ -- The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 9, 2021 /PRNewswire/ -- The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a comprehensive overview of the size of the SARS-CoV-2 (COVID-19) Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials.
  • This analysis indicates that the global COVID-19 vaccine market was worth $59 billion in 2021.
  • The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026.

106 COVID VARIANTS IDENTIFIED IN 12 U.S. STATES

Retrieved on: 
Tuesday, March 9, 2021
SARS-CoV-2, Variants of SARS-CoV-2, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Occupational safety and health, Coronavirus disease

MAKO Medical has sequenced more than 700 COVID samples, finding 285 variant occurrences.

Key Points: 
  • MAKO Medical has sequenced more than 700 COVID samples, finding 285 variant occurrences.
  • As reported, the B.1.1.7 variant was first detected in the United Kingdom in September 2020 and, as of March 4, has been identified in 2,672 individuals across forty-eight states in the United States.
  • The B.1.429 variant was first identified in late 2020 and is being actively studied by the CDC and researchers to better understand how it is different from other variants.
  • According to reports, this variant has been previously identified in multiple countries, including the United States.

North America Liquid Hand Soap Market Report 2021: Growth, Trends, COVID-19 Impact, and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 9, 2021
Cosmetics, Retail, Home Goods, Specialty, Public health, Hygiene, Hand, Health, Skin care, Cleaning products, Bathing, Hand washing, Soap, Coronavirus disease

The "North America Liquid Hand Soap Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Liquid Hand Soap Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The global pandemic COVID-19 has made a significant impact on the liquid hand soap market growth in the North American marketplace.
  • Moreover, sighting the rising demand for liquid hand soap and other hand hygiene products, market players are rapidly investing in introducing liquid hand wash solutions with quick action against viruses, bacteria, and pathogens.
  • The North American liquid hand soap has witnessed a shift in consumer preference toward hand hygiene products, such as liquid hand soap.

Battelle’s Multiple Assays Play a Critical Role in Assessing COVID-19 Vaccine Candidates

Retrieved on: 
Tuesday, March 9, 2021
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Health sciences, Natural sciences, Health, Coronavirus disease, Occupational safety and health, Public health, Zoonoses, COVID-19 vaccines, Assay, COVID-19 vaccine, Draft:BioAgilytix

The assay is particularly useful for testing samples from vaccine clinical trials.

Key Points: 
  • The assay is particularly useful for testing samples from vaccine clinical trials.
  • Assays, which determine the presence, amount, or function of a substance in a sample, are critically important in COVID-19 research.
  • They are used in diagnostics to assess the effectiveness of potential therapeutics and to determine immune response to vaccine candidates.
  • When the novel coronavirus that causes COVID-19 emerged a year ago, no assays existed for it.

Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to Boost SARS-CoV-2 Variant Detection and Tracking Nationally

Retrieved on: 
Tuesday, March 9, 2021
Infectious diseases, Hospitals, Genetics, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Oncology, Medical specialties, Ruo, Vaccination, Vaccine, Coronavirus disease, Health

The Company is targeting SGS Panel sales at state and federal government laboratories, hospitals, academic institutions, and certified diagnostic laboratories.

Key Points: 
  • The Company is targeting SGS Panel sales at state and federal government laboratories, hospitals, academic institutions, and certified diagnostic laboratories.
  • Use of the SGS Panel is currently limited to research use only (RUO) and is not meant to be diagnostic.
  • Tracking and containing variant spread is especially important as the population builds national immunity via the vaccine rollout.
  • The Linea COVID-19 Selective Genomic Surveillance (SGS) Mutation Panel (the SGS Panel) is for Research Use Only (RUO) and shall not be used for clinical diagnostic purposes.

Biostrap CEO Goes Public With Biometric Changes After Contracting COVID-19 And Shares How His Wearable Alerted Him Prior To Diagnosis

Retrieved on: 
Tuesday, March 9, 2021
Respiratory diseases, Health, Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Coronavirus disease, Medical specialties

"It was Biostrap's early warning notification that prompted me to schedule a nasal swab test, which confirmed the positive diagnosis of SARS-CoV-2," Sameer Sontakey, Biostrap CEO, said.

Key Points: 
  • "It was Biostrap's early warning notification that prompted me to schedule a nasal swab test, which confirmed the positive diagnosis of SARS-CoV-2," Sameer Sontakey, Biostrap CEO, said.
  • Although most patients with COVID-19 present with mild symptoms, they still show significant biometric changes, including resting heart rate, heart rate variability, oxygen saturation, respiratory rate and arterial properties.
  • In addition to the maladaptive changes in Sontakey's biometric trends, his sleep quality declined; sleep disruptions and duration increased significantly.
  • The Biostrap app is available for iOS on the Apple App Store and Android on the Google Play Store.

Which Mask Should You Wear While Exercising?

Retrieved on: 
Tuesday, March 9, 2021
Fictional characters, Fiction, Occupational safety and health, The Mask, Coronavirus disease, Face masks during the COVID-19 pandemic

Whether it's a trip to the grocery store, at school, or during exercise, MindBeauty's AM99 mask is versatile and offers comfort and protection.

Key Points: 
  • Whether it's a trip to the grocery store, at school, or during exercise, MindBeauty's AM99 mask is versatile and offers comfort and protection.
  • In addition to the protectiona face mask provides, exercise can also help people stay healthy and fight this virus.
  • And, though it might feel foreign to wear a mask while exercising, it's a necessity to slow and stop the spread of COVID-19.
  • This durability makes the AM99 mask a great option for those who plan to wear it while exercising."

Halberd's CEO on The Stock Day Podcast Breaking Down 20X Neutralizing Affinity SARS-COV-2 Antibody

Retrieved on: 
Tuesday, March 9, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Virology, COVID-19 drug development, Biotechnology, Immune system, Monoclonal antibody, Peplomer, Coronavirus disease, Antibody

CEO and Chairman of the Company, William A Hartman, joined Stock Day host Everett Jolly.

Key Points: 
  • CEO and Chairman of the Company, William A Hartman, joined Stock Day host Everett Jolly.
  • Jolly began the interview by commenting on a recent announcement regarding the Company's proprietary monoclonal antibody against the SARS-COV-2 Spike protein, which demonstrated 20 times greater neutralizing affinity compared to their original antibody.
  • "In order to bring any product forward that requires FDA approval, you're talking about millions of dollars and potentially several years.
  • "We're going to work our way towards working with COVID, where we already have a much stronger antibody," continued Hartman.